Northwestern Medicine has started with the COVID-19 clinical trials for people who are willing to volunteer for the registry to prevent themselves from the virus. The research is sponsored by Feinberg and headed by Dr. Karen Kreuger, a physician, and instructor in infectious diseases at Feinberg School of Medicine, currently working as an investigator for the registry.
The goals of the research study are as follows: –
- To recruit 5000 volunteers from the Chicago area who are at risk of exposure or are potentially interested in volunteering in different studies for the prevention of infection.
- In need of community members who are dis-proportionally being affected by the infection which involves old-aged people, racial/ethnic groups like African American, Latinx, Indians, Black, Native Americans, and people suffering from underlying health issues.
- A sample of 5000 participants was taken into consideration so that it would help the researchers and medical experts for their further studies as said by Dr. Karen Kreuger. Thus, it’s beneficial from community and individuals’ health points of view, especially during this pandemic.
- All the participants who have signed up for the registry will be contacted once their health reports match with the needed health profile for the clinical trials.
The study focusses on old people and also highlights the classification of 18 years and above at-risk individuals are mentioned below: –
- Health care workers
- People working in grocery or another departmental store
- An employee in public transportation
- Factory worker
- Those who live or work in nursing homes and so on…
About the Phase 1, 2 and upcoming Phase 31. The results of phases 1 and 2 were published in the journal Lancet which reported that the vaccine was safe and triggered an immune response. The mechanism of immune response is illustrated below: –
- In the first 14 days, the vaccine triggered a T-cell response generating white blood cells (WBC’s) that attacked the infected cells. In the next 14 days, it provoked an antibody response where these antibodies work was to prevent the infected cells to get infected via a virus.
- The first study of Phase 3 is expected to be launched in August where it aims will be to investigate the efficiency of vaccine which is developed by Oxford University’s Jenner Institute in collaboration with the pharmaceutical company Astra Zeneca.
- The venue for Phase 3 is announced as the Downtown Chicago Campus, Lake Forest Hospital & Central DuPage Hospital.
LONG TERM GOAL RELATED TO VACCINE
Oxford is working with the pharmaceutical company Astra Zeneca to develop, manufacture, and produce the vaccine on a large scale. By early next year, it has an aim to release 2 billion vaccine doses globally via partnerships with the manufacturers in several countries.
STAY SAFE! STAY HEALTHY! STAY TUNED!